Pancreatitis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pancreatitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Pancreatitis - Pipeline Review, H2 2016', provides an overview of the Pancreatitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Pancreatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pancreatitis
- The report reviews pipeline therapeutics for Pancreatitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Pancreatitis therapeutics and enlists all their major and minor projects
- The report assesses Pancreatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pancreatitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pancreatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pancreatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pancreatitis Overview 8
Therapeutics Development 9
Pipeline Products for Pancreatitis - Overview 9
Pipeline Products for Pancreatitis - Comparative Analysis 10
Pancreatitis - Therapeutics under Development by Companies 11
Pancreatitis - Therapeutics under Investigation by Universities/Institutes 13
Pancreatitis - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Pancreatitis - Products under Development by Companies 17
Pancreatitis - Products under Investigation by Universities/Institutes 18
Pancreatitis - Companies Involved in Therapeutics Development 19
Angion Biomedica Corp. 19
Atox Bio Ltd. 20
Bharat Serums And Vaccines Limited 21
CalciMedica, Inc. 22
Dynavax Technologies Corporation 23
Generon (Shanghai) Corporation Ltd. 24
GlaxoSmithKline Plc 25
LipimetiX Development Inc 26
Novartis AG 27
Pharming Group N.V. 28
Sun BioPharma, Inc. 29
Pancreatitis - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
AB-103 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
AEM-2802 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
AEM-2814 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ANG-3070 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
C1 esterase inhibitor (recombinant) - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
CM-128 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
DV-1179 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
F-637 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
GSK-180 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
GSK-2795039 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
GSK-6288B - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ND-07 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
P-2pal18S - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
PZ-235 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
SBP-101 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
SBP-102 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecule to Inhibit Cyclophilin D for Acute Pancreatitis - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Small Molecules to Inhibit Trypsin for Pancreatitis - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
SP-20201 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
ulinastatin - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Withaferin A - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Pancreatitis - Dormant Projects 73
Pancreatitis - Discontinued Products 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables

Number of Products under Development for Pancreatitis, H2 2016 9
Number of Products under Development for Pancreatitis - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Comparative Analysis by Unknown Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Pancreatitis - Pipeline by Angion Biomedica Corp., H2 2016 19
Pancreatitis - Pipeline by Atox Bio Ltd., H2 2016 20
Pancreatitis - Pipeline by Bharat Serums And Vaccines Limited, H2 2016 21
Pancreatitis - Pipeline by CalciMedica, Inc., H2 2016 22
Pancreatitis - Pipeline by Dynavax Technologies Corporation, H2 2016 23
Pancreatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 24
Pancreatitis - Pipeline by GlaxoSmithKline Plc, H2 2016 25
Pancreatitis - Pipeline by LipimetiX Development Inc, H2 2016 26
Pancreatitis - Pipeline by Novartis AG, H2 2016 27
Pancreatitis - Pipeline by Pharming Group N.V., H2 2016 28
Pancreatitis - Pipeline by Sun BioPharma, Inc., H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Stage and Target, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 34
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 38
Pancreatitis - Dormant Projects, H2 2016 73
Pancreatitis - Discontinued Products, H2 2016 74